Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

SPINOSAD 0.9% TOPICAL SUSP

spinosad
$1.9697per ML

Strength

9 mg/mL

Manufacturer

Allegis Pharmaceuticals, LLC

NDC

28595057004

Classification

Generic

Dosage Form

SUSPENSION

Route

TOPICAL

Last Updated

4/22/2026

Active Ingredients

SPINOSAD

Approval Type

Authorized Generic (NDA)

FDA Application

NDA022408

On Market Since

6/25/2014

Pharmacological Classes

Pediculicide

Price History

1W

0.0%

1M

+2.3%

3M

+4.7%

6M

+4.4%

1Y

+14.5%

3Y

+14.5%

5Y

+14.5%

All

+29.3%

Generic Alternatives

1 alternative • Same active ingredient

SPINOSAD 0.9% TOPICAL SUSP
Generic
52246057004•ParaPRO LLC
$1.9697

Related Drugs

Same classification

ITCH-X GEL
Generic
00225049533•BF ASCHER AND CO INC
$0.0816
per GM
IVERMECTIN 0.5% LOTION
Generic
51672423008•Sun Pharmaceutical Industries Inc.
$1.2913
per GM
IVERMECTIN 3 MG TABLET
Generic
42799080601•Edenbridge Pharmaceuticals LLC
$2.2926
per EA
IVERMECTIN 3 MG TABLET
Generic
72888020666•Advagen Pharma Ltd.
$2.2926
per EA
IVERMECTIN 3 MG TABLET
Generic
75907016721•Dr. Reddy's Laboratories Inc.
$2.2926
per EA
IVERMECTIN 1% CREAM
Generic
00591405289•Actavis Pharma, Inc.
$2.9941
per GM
IVERMECTIN 1% CREAM
Generic
45802010284•Padagis Israel Pharmaceuticals Ltd
$2.9941
per GM
IVERMECTIN 1% CREAM
Generic
68308070145•Mayne Pharma
$2.9941
per GM
IVERMECTIN 1% CREAM
Generic
72578012008•Viona Pharmaceuticals Inc.
$2.9941
per GM

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy